文献速递眼底病与葡萄膜炎

视觉周期调控的进展与治疗机遇

Advances and therapeutic opportunities in visual cycle modulation.
PubMed 文献 · Prog Retin Eye Res · 2025-04-23

视觉周期通过再生11-顺式视黄醛维持持续视觉,但其通量可促成Stargardt病、年龄相关性黄斑变性和糖尿病视网膜病变等视网膜病变。本文综述当前及新兴视觉周期调节剂的药物化学、作用机制、临床前与临床研究疗效,并展望通过调控该生化通路安全有效保留视力的药物发现机遇。

要点

  • 视觉周期中间产物和副产物如脂褐素的双视黄素成分可蓄积并伴随细胞损伤及光感受器丢失。
  • 内在策略靶向RPE65、CRBP1及视紫红质抑制剂/拮抗剂等,外在策略如RBP4拮抗剂间接改变视网膜视黄醛可用性。
  • 多种药物在动物模型中显示减少病理改变和改善视网膜存活的希望,部分进入临床研究,但目前尚无FDA批准药物。

核心结论

  • 视觉周期调节是减缓或预防毒性中间产物形成以保留视网膜结构和功能的治疗策略,目前尚无FDA批准药物,挑战在于优化药物特异性和作用持续时间并最小化夜盲等副作用。

研究设计与样本

  • 综述,全面检视当前及新兴视觉周期调节剂,讨论其药物化学、作用机制、临床前和临床研究疗效及未来药物发现机遇。

主要发现

  • 视觉周期通量可促成Stargardt病、年龄相关性黄斑变性和糖尿病视网膜病变等视网膜病变,其中间产物和副产物如脂褐素双视黄素成分蓄积并伴随细胞损伤和光感受器丢失。
  • 过去二十年出现多种视觉周期调节策略,包括靶向色素上皮或光感受器内关键酶、视黄醛结合蛋白或受体的内在方法(如RPE65、CRBP1和视紫红质抑制剂/拮抗剂)以及间接改变视网膜视黄醛可用性的外在策略(如RBP4拮抗剂)。
  • 许多药物在视觉周期相关视网膜疾病动物模型中显示减少病理改变和改善视网膜存活的希望,部分已进入临床研究。

关键数值与推荐

  • 多种视觉周期调节剂在动物模型中显示减少病理改变和改善视网膜存活的希望,部分进入临床研究,但目前尚无FDA批准药物。
  • 挑战在于优化药物特异性和作用持续时间并最小化夜盲等副作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 目前尚无FDA批准药物。
  • 挑战在于优化药物特异性和作用持续时间并最小化夜盲等副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The visual cycle is a metabolic pathway that enables continuous vision by regenerating the 11-cis-retinal chromophore for photoreceptors opsins. Although integral to normal visual function, the flux of retinoids through this cycle can contribute to a range of retinal pathologies, including Stargardt disease, age-related macular degeneration, and diabetic retinopathy. In such conditions, intermediates and byproducts of the visual cycle, such as bisretinoid components of lipofuscin, can accumulate, concomitant with cellular damage and eventual photoreceptor loss. This has inspired efforts to modulate the visual cycle, aiming to slow or prevent the formation of these toxic intermediates and thus preserve retinal structure and function. Over the past two decades, multiple strategies to modulate the visual cycle have emerged. These include both intrinsic approaches, targeting key enzymes, retinoid-binding proteins, or receptors within the pigment epithelium or photoreceptors (e.g., RPE65, CRBP1, and rhodopsin inhibitors/antagonists) and extrinsic strategies that indirectly alter retinoid availability within the retina (e.g., RBP4 antagonists). Many of these agents have shown promise in animal models of visual cycle-associated retinal diseases, reducing pathological changes, and improving retinal survival. Several have advanced into clinical studies, although none are currently FDA-approved. Challenges remain in optimizing drug specificity and duration of action while minimizing side effects such as nyctalopia. In this review, we comprehensively examine current and emerging visual cycle modulators, discuss their medicinal chemistry, mechanisms of action, efficacy in preclinical and clinical studies, and highlight future opportunities for drug discovery aimed at safely and effectively preserving vision through modulation of this biochemical pathway.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Zaluski J, Bassetto M, Kiser PD, et al. Advances and therapeutic opportunities in visual cycle modulation. Prog Retin Eye Res. 2025. PMID: 40280538. doi:10.1016/j.preteyeres.2025.101360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。